BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 10869631)

  • 1. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center.
    Freedland SJ; Jalkut M; Dorey F; Sutter ME; Aronson WJ
    Urology; 2000 Jul; 56(1):87-91. PubMed ID: 10869631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Amling CL; Dorey F; Kane CJ; Presti JC; Terris MK; Aronson WJ;
    Urology; 2002 Oct; 60(4):670-4. PubMed ID: 12385931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multivariate analysis of race and adverse pathologic findings after radical prostatectomy.
    Freedland SJ; Dorey F; Aronson WJ
    Urology; 2000 Nov; 56(5):807-11. PubMed ID: 11068307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score.
    Freedland SJ; Csathy GS; Dorey F; Aronson WJ
    J Urol; 2002 Feb; 167(2 Pt 1):516-20. PubMed ID: 11792909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy.
    Freedland SJ; Dorey F; Aronson WJ
    Urology; 2001 Mar; 57(3):476-80. PubMed ID: 11248623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical stage T1c prostate cancer: pathologic outcomes following radical prostatectomy in black and white men.
    Eastham JA; Carver B; Katz J; Kattan MW
    Prostate; 2002 Mar; 50(4):236-40. PubMed ID: 11870801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database.
    Hamilton RJ; Aronson WJ; Presti JC; Terris MK; Kane CJ; Amling CL; Freedland SJ
    Cancer; 2007 Nov; 110(10):2202-9. PubMed ID: 17876838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen.
    Freedland SJ; Terris MK; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Aronson WJ;
    J Urol; 2004 Jun; 171(6 Pt 1):2215-20. PubMed ID: 15126788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database.
    Freedland SJ; Presti JC; Amling CL; Kane CJ; Aronson WJ; Dorey F; Terris MK;
    Urology; 2003 Apr; 61(4):736-41. PubMed ID: 12670557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database.
    Freedland SJ; Aronson WJ; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Terris MK;
    Urology; 2003 Apr; 61(4):742-7. PubMed ID: 12670558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database.
    Freedland SJ; Vidal AC; Howard LE; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Aronson WJ;
    Cancer; 2017 Nov; 123(21):4199-4206. PubMed ID: 28654204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer.
    Tewari A; Horninger W; Badani KK; Hasan M; Coon S; Crawford ED; Gamito EJ; Wei J; Taub D; Montie J; Porter C; Divine GW; Bartsch G; Menon M
    BJU Int; 2005 Jul; 96(1):29-33. PubMed ID: 15963115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.
    Moul JW; Sesterhenn IA; Connelly RR; Douglas T; Srivastava S; Mostofi FK; McLeod DG
    JAMA; 1995 Oct; 274(16):1277-81. PubMed ID: 7563532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Black and White men younger than 50 years of age demonstrate similar outcomes after radical prostatectomy.
    Moses KA; Chen LY; Sjoberg DD; Bernstein M; Touijer KA
    BMC Urol; 2014 Dec; 14():98. PubMed ID: 25495177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease recurrence in black and white men undergoing radical prostatectomy for clinical stage T1-T2 prostate cancer.
    Eastham JA; Kattan MW
    J Urol; 2000 Jan; 163(1):143-5. PubMed ID: 10604332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.